US20120252862A1 - Dissolvable Film Strip Comprising Natural Components - Google Patents

Dissolvable Film Strip Comprising Natural Components Download PDF

Info

Publication number
US20120252862A1
US20120252862A1 US13/498,900 US201013498900A US2012252862A1 US 20120252862 A1 US20120252862 A1 US 20120252862A1 US 201013498900 A US201013498900 A US 201013498900A US 2012252862 A1 US2012252862 A1 US 2012252862A1
Authority
US
United States
Prior art keywords
film strip
strip according
film
natural
natural component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/498,900
Inventor
Erdem Yesilada
Gulengul Duman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeditepe Universitesi
Original Assignee
Yeditepe Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeditepe Universitesi filed Critical Yeditepe Universitesi
Priority claimed from PCT/IB2010/054121 external-priority patent/WO2011036599A1/en
Assigned to YEDITEPE UNIVERSITESI reassignment YEDITEPE UNIVERSITESI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUMAN, GULENGUL, YESILADA, ERDEM
Publication of US20120252862A1 publication Critical patent/US20120252862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to film strips which comprise natural product formulations and can be absorbed from oral mucosa.
  • melatonin is the compound which has the most potent natural cell-protecting and anti-carcinogenic effect known.
  • the melatonin compound shows its effect by enabling the free radicals to be removed.
  • Melatonin is a hormone which is secreted at night in the human body. It came out in postmortem studies that the melatonin level is higher in people died at night. The average plasma melatonin level in adults is about 60 to 70 pg/ml.
  • resveratrol Another component having potent antioxidant effect is resveratrol.
  • resveratrol in the structure of red wine which is a natural product.
  • Soil products used in making red wine may vary according to soil conditions, growing and climate conditions, even years.
  • proanthocyanidins which give the red color and the astringent taste to red wine. These substances also have potent antioxidant properties.
  • green tea is a natural product which has potent antioxidant property.
  • alkaloids such as caffeine in green tea, besides catechin together with EGCG (epigallocatechin gallate) and flavonoides.
  • Use of green tea extract especially with the aim of weight-loss is becoming widespread recently, owing to its lipolytic property which has been determined scientifically in recent years.
  • Drugs used in treatment of diseases in pharmacological field can be prepared in different forms such as tablets, syrups, powders, etc. Some problems may be confronted during application of these drugs. Depending on the interaction of the drugs with food, their absorption in the stomach reduces and thus bioavailability of drugs in the body does not occur sufficiently. In order that bioavailability of drugs to be efficacious, nutrients or drugs should be given to the body in optimum amounts. For example, in order that the daily amount of resveratrol which is recommended to the user can be taken in natural ways, people need to consume 500-1000 ml red wine every day. In this case, serious health problems may occur such as liver damage depending on the alcohol taken. On the other hand, there is no resveratrol in each red wine.
  • the wine consumed comprises resveratrol or not.
  • it is needed to consume a great quantity of green tea may lead to serious problems in liver and kidney functions.
  • Consuming green tea in high quantity may also lead to constipation problem.
  • Another problem occurring during use of drugs is that, when the pills that are taken into the body by oral route are not swallowed with water they show ulceration effect. Depending on the formulation of the drug, the lesion effect may increase too.
  • pullulan structures in polysaccharide structure of which there is a polymer that does not have a pharmacological effect and which is composed of maltotriose molecules. They are on the market as film strips which can be absorbed from oral mucosa.
  • Listerine® is a product of pullulan structure which is used for oral hygiene and can be absorbed from oral mucosa. The said product is of daily use in order to give aroma to the mouth.
  • the Unites States patent document no. US2009004254 A1 discloses active drugs in the form of film which are orally-dissolvable and edible.
  • the said film takes form with a water-soluble polymer.
  • the said drug comprises a binding agent which is dissolvable in the mouth of the patient and an active drug dispersed in this agent thus pharmacologically effective dose of the drug is taken into the body by dissolving in the mouth of the patient.
  • JP63093717 A an application in the state of the art, discloses an agent comprising polymaltotriose and showing high adhesive property in oral mucosa. This agent can be used to fix the drugs to the mucosa in oral cavity. This adhesive agent can be applied by being added to the drug for treatment.
  • the objective of the present invention is to realize a film strip which shows a potent antioxidant effect in a short time by being absorbed rapidly when it is applied from the oral mucosa at lower dosages than the dosage forms known and which comprises natural components.
  • Another objective of the present invention is to realize a film strip which shows a rapid effect without undergoing digestive processes in stomach and intestine and which comprises natural components.
  • Yet another objective of the invention is to realize a film strip which can be carried easily and which comprises natural components.
  • a further objective of the invention is to realize a film strip which can be taken by oral route without needing water and which comprises natural components.
  • a yet further objective of the invention is to realize a film strip which has a potent antioxidant effect and which comprises natural components.
  • a still further objective of the invention is to realize a natural film strip wherein no filler or additive is used.
  • An additional objective of the invention is to realize a film strip which is easy to produce.
  • the mixture of natural component freeze dried by means of lyophilization and maltotriose polymers known as melatonin powder is mixed with distilled water in an amount between 0.001-0.5 g/ml.
  • the obtained mixture is poured over a smooth flat and non-adhesive layer in the form of a thin film.
  • the poured film is freeze dried in drying oven at relative humidity of 50% and room temperature overnight.
  • the obtained film is cut thinly.
  • a natural component-maltotriose complex is obtained in the form of a thin film.
  • the obtained film strip is elastic, adhesive and easily orally-dissolvable.
  • the natural component is red wine.
  • Red wine is freeze dried by means of lyophilization and red wine powder is mixed with maltotriose polymer such that it will provide the amount of resveratrol that a person should take. Consequently, red wine-maltotriose complex is obtained.
  • maltotriose polymer such that it will provide the amount of resveratrol that a person should take. Consequently, red wine-maltotriose complex is obtained.
  • There is no resveratrol in all wines however, it was determined that there is high proportion of resveratrol substance in wines made of Bo azkere and ⁇ küzgözü grapes which are produced in Turkey. Since there is no resveratrol in all wines, the wine to be lyophilized is chosen from Bo azkere and ⁇ küzgözü which are indigenous grape types.
  • Absorption of resveratrol from the gastrointestinal system occurs in small intestine only in the ratio of 20%. It is known that the oral bioavailability of the resveratrol in powder form is low however its absorption from the mouth is known to increase by the changes made in the formulation (for example liposomal resveratrol). A higher level of absorption is provided when resveratrol inside red wine is applied orally in the form of a film strip, in comparison with the absorption from gastrointestinal system. Procyanidinins provided in the composition of red wine will increase absorption of resveratrol and contribute to effect owing to its antioxidant property as well. Furthermore, since the components in the film strip mix with blood directly upon being absorbed from the mouth they don't undergo gastrointestinal metabolism (first-pass metabolism). Thus the liver doesn't get tired and potential toxicity risks which may be caused by metabolites in the body can be eliminated.
  • the film strip in the structure of the red wine-maltotriose complex has the following effects: it dilutes blood (anti-platelet) in cardiovascular diseases, reduces the risk of heart attack depending on the antioxidant effect, increases good cholesterol (HDL) and prevents oxidation of bad cholesterol (LDL).
  • ADDL good cholesterol
  • LDL low cholesterol
  • green tea comprising EGCG (EpiGallo Catechin Gallate) agent is used.
  • the green tea extract is freeze dried by means of lyophilization and the green tea powders are mixed with maltotriose polymer such that it will provide the amount of EGCG (EpiGallo Catechin Gallate) that a person should take.
  • the product obtained as a thin film is in the structure of green tea-maltotriose complex.
  • EGCG is safe to be applied up to 1600 mg as single oral dose.
  • Thin film strip comprising green tea is used with the aim of weight-loss owing to its lipolytic property.
  • the use of caffeine in cardio-paths (because increases blood pressure) or those with gastric problems (because increases gastric acid) usually poses a problem. Therefore in an embodiment of the present invention, thin film strips are obtained in the structure of EGCG-maltotriose complex using directly pure EGCG which does not comprise caffeine.
  • melatonin is chosen as the natural component. Bioavailability of melatonin by oral route is 15%. Its absorption is fast since it is taken from mouth directly in the form of film and its mixture with blood and efficacy are high. Melatonin is a natural cell-protecting hormone which is secreted in the human body. The scientific studies made put forward that it has potent antioxidant property and anticancer effect. Thin film strip comprising melatonin is an appropriate formulation form for melatonin the use of which is gradually increasing in recent years and it is a product form which provides fast efficacious and easy use in order to alleviate jet-lag complaints in especially intercontinental journeys.

Abstract

The present invention relates to film strips which comprise natural product formulations and can be absorbed from oral mucosa. The said film strip can be used with the aim of preventing and treating diseases in a short time, by being absorbed rapidly when it is applied from the oral mucosa at lower dosages than the dosage forms known.

Description

    FIELD OF THE INVENTION
  • The present invention relates to film strips which comprise natural product formulations and can be absorbed from oral mucosa.
    • BACKGROUND OF THE INVENTION
  • While the drugs are used in the treatment of diseases, some components provided in the structure thereof are taken into the body as well. Treatment of diseases can be possible by means of these active substances. For example, melatonin is the compound which has the most potent natural cell-protecting and anti-carcinogenic effect known. The melatonin compound shows its effect by enabling the free radicals to be removed. Melatonin is a hormone which is secreted at night in the human body. It came out in postmortem studies that the melatonin level is higher in people died at night. The average plasma melatonin level in adults is about 60 to 70 pg/ml. In addition, after it was claimed in 1978 that the breast cancer is a disease which emerges in the absence of melatonin, many clinical studies have been conducted in order to determine the melatonin secretion in cancer patients. In some human cell types, anti-tumor effects of pineal gland and melatonin were reported.
  • Another component having potent antioxidant effect is resveratrol. There is resveratrol in the structure of red wine which is a natural product. However there is no resveratrol in the composition of each red wine. Soil products used in making red wine may vary according to soil conditions, growing and climate conditions, even years. There are proanthocyanidins which give the red color and the astringent taste to red wine. These substances also have potent antioxidant properties.
  • Apart from these, green tea is a natural product which has potent antioxidant property. There are alkaloids such as caffeine in green tea, besides catechin together with EGCG (epigallocatechin gallate) and flavonoides. Use of green tea extract especially with the aim of weight-loss is becoming widespread recently, owing to its lipolytic property which has been determined scientifically in recent years.
  • Drugs used in treatment of diseases in pharmacological field can be prepared in different forms such as tablets, syrups, powders, etc. Some problems may be confronted during application of these drugs. Depending on the interaction of the drugs with food, their absorption in the stomach reduces and thus bioavailability of drugs in the body does not occur sufficiently. In order that bioavailability of drugs to be efficacious, nutrients or drugs should be given to the body in optimum amounts. For example, in order that the daily amount of resveratrol which is recommended to the user can be taken in natural ways, people need to consume 500-1000 ml red wine every day. In this case, serious health problems may occur such as liver damage depending on the alcohol taken. On the other hand, there is no resveratrol in each red wine. Therefore, it can not be known whether the wine consumed comprises resveratrol or not. Likewise, it can be possible to take EGCG into the body by consuming green tea in natural ways. However, it is needed to consume a great quantity of green tea. Consuming green tea in high quantity may lead to serious problems in liver and kidney functions. Consuming green tea in high quantity may also lead to constipation problem.
  • Another problem occurring during use of drugs is that, when the pills that are taken into the body by oral route are not swallowed with water they show ulceration effect. Depending on the formulation of the drug, the lesion effect may increase too.
  • However apart from these in drug property, there are pullulan structures in polysaccharide structure of which there is a polymer that does not have a pharmacological effect and which is composed of maltotriose molecules. They are on the market as film strips which can be absorbed from oral mucosa. For example, Listerine® is a product of pullulan structure which is used for oral hygiene and can be absorbed from oral mucosa. The said product is of daily use in order to give aroma to the mouth.
  • The Unites States patent document no. US2009004254 A1, an application in the state of the art, discloses active drugs in the form of film which are orally-dissolvable and edible. The said film takes form with a water-soluble polymer. The said drug comprises a binding agent which is dissolvable in the mouth of the patient and an active drug dispersed in this agent thus pharmacologically effective dose of the drug is taken into the body by dissolving in the mouth of the patient.
  • The Japanese patent document no. JP63093717 A, an application in the state of the art, discloses an agent comprising polymaltotriose and showing high adhesive property in oral mucosa. This agent can be used to fix the drugs to the mucosa in oral cavity. This adhesive agent can be applied by being added to the drug for treatment.
    • SUMMARY OF THE INVENTION
  • The objective of the present invention is to realize a film strip which shows a potent antioxidant effect in a short time by being absorbed rapidly when it is applied from the oral mucosa at lower dosages than the dosage forms known and which comprises natural components.
  • Another objective of the present invention is to realize a film strip which shows a rapid effect without undergoing digestive processes in stomach and intestine and which comprises natural components.
  • Yet another objective of the invention is to realize a film strip which can be carried easily and which comprises natural components.
  • A further objective of the invention is to realize a film strip which can be taken by oral route without needing water and which comprises natural components.
  • A yet further objective of the invention is to realize a film strip which has a potent antioxidant effect and which comprises natural components.
  • A still further objective of the invention is to realize a natural film strip wherein no filler or additive is used.
  • An additional objective of the invention is to realize a film strip which is easy to produce.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In the preparation of the inventive orally-absorbable film strip, the mixture of natural component freeze dried by means of lyophilization and maltotriose polymers known as melatonin powder is mixed with distilled water in an amount between 0.001-0.5 g/ml. The obtained mixture is poured over a smooth flat and non-adhesive layer in the form of a thin film. The poured film is freeze dried in drying oven at relative humidity of 50% and room temperature overnight. The obtained film is cut thinly. Eventually, a natural component-maltotriose complex is obtained in the form of a thin film. The obtained film strip is elastic, adhesive and easily orally-dissolvable.
  • In an embodiment of the inventive orally-absorbable film strip, the natural component is red wine. Red wine is freeze dried by means of lyophilization and red wine powder is mixed with maltotriose polymer such that it will provide the amount of resveratrol that a person should take. Consequently, red wine-maltotriose complex is obtained. There is no resveratrol in all wines, however, it was determined that there is high proportion of resveratrol substance in wines made of Bo
    Figure US20120252862A1-20121004-P00001
    azkere and Öküzgözü grapes which are produced in Turkey. Since there is no resveratrol in all wines, the wine to be lyophilized is chosen from Bo
    Figure US20120252862A1-20121004-P00001
    azkere and Öküzgözü which are indigenous grape types. Absorption of resveratrol from the gastrointestinal system occurs in small intestine only in the ratio of 20%. It is known that the oral bioavailability of the resveratrol in powder form is low however its absorption from the mouth is known to increase by the changes made in the formulation (for example liposomal resveratrol). A higher level of absorption is provided when resveratrol inside red wine is applied orally in the form of a film strip, in comparison with the absorption from gastrointestinal system. Procyanidinins provided in the composition of red wine will increase absorption of resveratrol and contribute to effect owing to its antioxidant property as well. Furthermore, since the components in the film strip mix with blood directly upon being absorbed from the mouth they don't undergo gastrointestinal metabolism (first-pass metabolism). Thus the liver doesn't get tired and potential toxicity risks which may be caused by metabolites in the body can be eliminated.
  • The film strip in the structure of the red wine-maltotriose complex has the following effects: it dilutes blood (anti-platelet) in cardiovascular diseases, reduces the risk of heart attack depending on the antioxidant effect, increases good cholesterol (HDL) and prevents oxidation of bad cholesterol (LDL). In addition, it has been put forward by scientific studies that it has preventive and therapeutic effects in pathologies such as particularly smoking related cancers and prostate and anti-aging effect depending on the antioxidant effect thereof.
  • In another embodiment of the invention, green tea comprising EGCG (EpiGallo Catechin Gallate) agent is used. Accordingly, the green tea extract is freeze dried by means of lyophilization and the green tea powders are mixed with maltotriose polymer such that it will provide the amount of EGCG (EpiGallo Catechin Gallate) that a person should take. The product obtained as a thin film is in the structure of green tea-maltotriose complex.
  • It is reported that EGCG is safe to be applied up to 1600 mg as single oral dose.
  • Thin film strip comprising green tea is used with the aim of weight-loss owing to its lipolytic property. However, the use of caffeine in cardio-paths (because increases blood pressure) or those with gastric problems (because increases gastric acid) usually poses a problem. Therefore in an embodiment of the present invention, thin film strips are obtained in the structure of EGCG-maltotriose complex using directly pure EGCG which does not comprise caffeine.
  • In another embodiment of the inventive orally-absorbable film strip, melatonin is chosen as the natural component. Bioavailability of melatonin by oral route is 15%. Its absorption is fast since it is taken from mouth directly in the form of film and its mixture with blood and efficacy are high. Melatonin is a natural cell-protecting hormone which is secreted in the human body. The scientific studies made put forward that it has potent antioxidant property and anticancer effect. Thin film strip comprising melatonin is an appropriate formulation form for melatonin the use of which is gradually increasing in recent years and it is a product form which provides fast efficacious and easy use in order to alleviate jet-lag complaints in especially intercontinental journeys.

Claims (15)

1.-13. (canceled)
14. A film strip comprising elastic, adhesive and orally-dissolvable natural components and obtained by carrying out the processes of
mixing a natural component freeze dried by means of lyophilization, with a maltotriose polymer and water,
pouring the mixture in the form of a thin film, and
drying the poured thin film.
15. The film strip according to claim 14, characterized in that the mixture ratio of natural component-maltotriose polymer is in the range of 0.001-0.5 g/ml.
16. The film strip according to claim 15, characterized in that the natural component lyophilized is resveratrol.
17. The film strip according to claim 16, characterized in that the natural component is red wine comprising resveratrol.
18. The film strip according to claim 15, characterized in that the natural component lyophilized is EGCG (EpiGallo Catechin Gallate).
19. The film strip according to claim 18, characterized in that the natural component is green tea comprising EGCG.
20. The film strip according to claim 15, characterized in that the natural component lyophilized is melatonin.
21. The film strip according to claim 17, characterized in that it is used to reduce the risk of heart attack, increase good cholesterol (HDL), prevent oxidation of bad cholesterol (LDL) and dilute the blood in cardiovascular diseases (antiplatelet).
22. The film strip according to claim 17, characterized in that it is used as a prophylactic and an adjuvant to treatment in a plurality of cancers including prostate disease.
23. The film strip according to claim 17, characterized in that it is used for anti-aging depending on an antioxidant effect thereof.
24. The film strip according to claim 18, characterized in that it is used in weight-loss programs with its lipolytic property.
25. The film strip according to claim 19, characterized in that it is used in weight-loss programs with its lipolytic property.
26. The film strip according to claim 20, characterized in that it is used as a natural cell-protector and an anti-carcinogen.
27. The film according to claim 20, characterized in that it is used to alleviate jet-lag effects in a body by enabling free radicals to be removed from the body.
US13/498,900 2009-09-28 2010-09-14 Dissolvable Film Strip Comprising Natural Components Abandoned US20120252862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR200997338 2009-09-28
TR2009/97338 2009-09-28
PCT/IB2010/054121 WO2011036599A1 (en) 2009-09-28 2010-09-14 A dissolvable film strip comprising natural components

Publications (1)

Publication Number Publication Date
US20120252862A1 true US20120252862A1 (en) 2012-10-04

Family

ID=46928039

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/498,900 Abandoned US20120252862A1 (en) 2009-09-28 2010-09-14 Dissolvable Film Strip Comprising Natural Components

Country Status (1)

Country Link
US (1) US20120252862A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734208B2 (en) * 1997-04-11 2004-05-11 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO2005082407A1 (en) * 2003-11-03 2005-09-09 Musc Foundation For Research Development Use of quercetin and resveratrol to treat and prevent oral cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734208B2 (en) * 1997-04-11 2004-05-11 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO2005082407A1 (en) * 2003-11-03 2005-09-09 Musc Foundation For Research Development Use of quercetin and resveratrol to treat and prevent oral cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anli et al., Journal of Wine Research vol 17, No. 2, pages 117-125, publication year: 2006 *
Elattar TM and Virji AS (1999) Anticancer Res Nov-Dec; 19 (6B) pages 5407-5414 *
Rekha MR and Sharma P (2007) Trends Biomater. Artif. Organs Vol 20 (2) pages 1-6 *
Wang et al. (2003) Arch Otolaryngol Head Neck Surg Vol 129 pages 1-8 *

Similar Documents

Publication Publication Date Title
Mallery et al. Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze dried black raspberries: implications for oral cancer chemoprevention
Manifar et al. Curcumin gel in the treatment of minor aphthous ulcer: A randomized, placebo-controlled trial
US20190008907A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
WO2006013420A3 (en) Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph)
WO2019199260A2 (en) Formulations comprising herbal extracts
EP2908833B1 (en) Formulations comprising herbal extracts
EP1928250A2 (en) Berry preparations and extracts
WO2005084703A1 (en) Sustained-release composition for oral cavity
JP7020915B2 (en) Soluble and stable pharmaceutical compositions that are anti-inflammatory, proliferative, protective and mucosal adherent, their use and acquisition methods for treating the condition of mucosal sites, and basic pharmaceutical compositions for the preparation of pharmaceutical compositions. Things and how to get them
US20160101048A1 (en) +l-carnosine zinc formulations and methods of use
JP2007308426A (en) Ointment for ameliorating or treating tumor in oral cavity
RU2465912C1 (en) Pharmaceutical composition based on epigallocatechinegallate-containing nanomicelles and its application for treatment of atopic dermatitis, crohn's disease, adenomyosis and hyperplastic diseases of prostate
AU2016307998B2 (en) Composition comprising tannins
US20120252862A1 (en) Dissolvable Film Strip Comprising Natural Components
JP2012521424A (en) Methods and compositions for the treatment of cancer
WO2011036599A1 (en) A dissolvable film strip comprising natural components
Grossberg et al. The essential herb-drug-vitamin interaction guide: the safe way to use medications and supplements together
Shaik et al. Cordycepin-melittin nanoconjugate intensifies wound healing efficacy in diabetic rats
JP3522186B2 (en) Propolis preparation and method for producing the same
EP3829615B1 (en) Composition for oral administration comprising one or more cannabinoids
TWI829731B (en) Composition
CN101669915A (en) Oridonin dry emulsion and preparation method thereof
Predut et al. Assessment of the cytotoxic potential of rutin formulations on human oral cells.
Radhika Mucoadhesive Buccal Films Embedded with 5-Fluorouracil Liposomes Formulation and Characterization
WO2023249591A1 (en) An encapsulated pharmaceutical compound for treating drymouth and symptoms caused by systemic diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: YEDITEPE UNIVERSITESI, TURKEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YESILADA, ERDEM;DUMAN, GULENGUL;REEL/FRAME:028437/0041

Effective date: 20120403

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION